As an Associate Partner in L2 Consulting, Dr. Nick Gaspar comes with an established track record as a successful research scientist and leader in biopharmaceutical discovery and development. His industry experience spans 22 years in 5biotech/pharma companies, where he applied his core strengthsin molecular and cellular biology, immunology, biochemistry and assay development to advance therapeutics in the early and late stages of the drug development process. During his 10 year tenure at Scios/J&J, he led the Bioanalytical group in CMC, which developed the cell-based potency assay for the FDA approved drug Natrecor, and he led a Discovery Research team, which demonstrated the efficacy and MOA of small molecule inhibitors of the TGF and p38 pathways for the treatment of various cancers, as well as fibrotic diseases, and inflammation.

Additionally, he has over 12 years of experience in other companies, developing oncolytic viruses and tumor antigen-expressing viruses for cancer immunotherapy, as well as antibodies for cancer. He led groups responsible for testing clinical study samples under GLPs or manufactured drug product under GMP’s. In these capacities he applied his expertise in assay development and practical application of GXP’s to successfully complete testing programs. He has in-depth knowledge of developing and validated methods for qPCR, PK/PD, immunogenicity, neutralizing antibodies and potency testing and a proven track record of supporting regulatory filings.

Dr. Gaspar received his doctorate in Biochemistry and Molecular Biology from the University of California, Davis. He has been an invited to speak at international conferences where he presented his research on TGF inhibitors for treatment of pancreatic cancer and fibrotic diseases and also his approaches to Biological Assay Development and Validation. He has published his work in Molecular Pharmacology, the Journal of Biochemistry, and other journals.

Nicolas Gaspar PhD